|
|
Article: Accentia Biopharmaceuticals Acquires Worldwide Exclusive License to Revimmune for All Autoimmune Diseases.
- Article from:
- Business Wire
- Article date:
- February 28, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Revimmune uses an approved drug in a new patent-pending method to eliminate autoimmunity: In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune improves function in most patients and stops progression in over 90% of cases refractory to standard therapies
Licensed technology applicable to 80 autoimmune diseases: long-term follow-up in severe, refractory, life-threatening autoimmune aplastic anemia demonstrates 70% of patients maintain complete remissions
TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has acquired the exclusive worldwide rights for Revimmune[TM], a patent-pending pharmaceutical treatment in ...